search
Back to results

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

Primary Purpose

Skin Cancer, Melanoma, Lentigo Maligna

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Reflectance confocal microscopy
Sponsored by
Lucid, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Skin Cancer focused on measuring skin disorders, skin cancer, melanoma, lentigo maligna

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing biopsy for a pigmented lesion suspicious for malignancy.
  • Patients undergoing biopsy on an anatomical site that is readily accessible to the VivaScope 1500 (for example, chest, back, legs, arms, cheek, forehead).
  • Ability to give informed consent.

Exclusion Criteria:

  • Lesion suspicious for melanoma located on a site that is not amenable to confocal imaging (for example, adjacent to the nose, ears or eyes, fingers, toes).
  • The lesion (suspicious for melanoma) is located on soles of the feet or palms of the hands.
  • Inability to give informed consent.
  • Known hypersensitivity to adhesive rings.

Sites / Locations

  • Loma Linda University
  • VA Loma Linda Health Care System
  • Skin and Cancer Assoicates
  • Memorial Sloan-Kettering Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • University of Rochester Medical Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

1

Arm Description

Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo

Outcomes

Primary Outcome Measures

To assess the diagnostic accuracy of reflectance confocal scanning laser microscopy(RCM) for melanoma diagnosis when compared to the "gold standard" histopathologic diagnosis.

Secondary Outcome Measures

To assess interobserver variability associated with interpreting confocal images for detecting cutaneous melanoma and to assess confocal correlations in a qualitative manner.

Full Information

First Posted
November 4, 2008
Last Updated
October 2, 2012
Sponsor
Lucid, Inc.
Collaborators
Memorial Sloan Kettering Cancer Center, Loma Linda University, University of Rochester, VA Loma Linda Health Care System, Skin and Cancer Associates in Plantation,Fl., Harvard University
search

1. Study Identification

Unique Protocol Identification Number
NCT00785369
Brief Title
In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis
Official Title
In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lucid, Inc.
Collaborators
Memorial Sloan Kettering Cancer Center, Loma Linda University, University of Rochester, VA Loma Linda Health Care System, Skin and Cancer Associates in Plantation,Fl., Harvard University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to image pigmented skin lesions suspicious for melanoma with an imaging technology called in vivo reflectance confocal microscopy. This technology uses low intensity laser to image below the surface of the skin. The confocal images of the suspicious skin lesion will be examined. The goal of this study is to compare the results of the confocal image examination to the pathologic diagnosis of the skin lesion. The technique being evaluated in this study uses reflectance confocal microscopy in vivo. The term "in vivo" means in/on a living subject. In this study you will be the living subject and the confocal microscope will be placed on your skin to look at your skin lesion. The confocal microscope uses a weak laser light and a sophisticated lens to image the individual cells that make up the skin. Your lesion will be photographed with high resolution photography.
Detailed Description
Patients will be imaged with the VivaScope 1500 reflectance confocal microscope during a single patient visit. The lesion will be photographed with high resolution photography and a high resolution dermoscopic device. The lesion will then be prepared for RCM imaging. A skin contact device consisting of a metal ring and window will be applied to the skin surrounding the lesion of interest with a disposable medical grade adhesive. A wetting solution will be placed onto the skin. The wetting solutions include a high index oil such as a clear cosmetic oil or mineral oil. A wetting solution such as ultrasound gel will also be placed on the lens of the microscope. Application of these agents diminishes artifacts caused by light scattering at the skin surface. RCM images of the lesion will be captured through the window/contact device using the Vivascope 1500 reflectance confocal microscope provided by Lucid, Inc. Two types of images will be collected, mosaics and stacks. Mosaics are 12x12 confocal images that are optically combined or "stitched" together to create a seamless representation of a 6mm x 6mm total area at specific depths within the skin. Stacks are 0.5mm x 0.5mm confocal images taken at 5 micron intervals from the keratin layer to the superficial dermis. Mosaics and stacks will be acquired for the skin lesion. The total estimated imaging time for a patient in this study is about 10 minutes for each lesion. More than one lesion may be imaged per patient. After the imaging is complete, the lesion will be biopsied. All lesion images will be saved on a network server for later review and analysis. All imaging will be completed by trained research staff familiar with confocal imaging.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Cancer, Melanoma, Lentigo Maligna
Keywords
skin disorders, skin cancer, melanoma, lentigo maligna

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
441 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Other
Arm Description
Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
Intervention Type
Device
Intervention Name(s)
Reflectance confocal microscopy
Other Intervention Name(s)
Device
Intervention Description
Reflectance confocal microscopy (VivaScope 1500)
Primary Outcome Measure Information:
Title
To assess the diagnostic accuracy of reflectance confocal scanning laser microscopy(RCM) for melanoma diagnosis when compared to the "gold standard" histopathologic diagnosis.
Time Frame
Once while on study
Secondary Outcome Measure Information:
Title
To assess interobserver variability associated with interpreting confocal images for detecting cutaneous melanoma and to assess confocal correlations in a qualitative manner.
Time Frame
Once while on study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing biopsy for a pigmented lesion suspicious for malignancy. Patients undergoing biopsy on an anatomical site that is readily accessible to the VivaScope 1500 (for example, chest, back, legs, arms, cheek, forehead). Ability to give informed consent. Exclusion Criteria: Lesion suspicious for melanoma located on a site that is not amenable to confocal imaging (for example, adjacent to the nose, ears or eyes, fingers, toes). The lesion (suspicious for melanoma) is located on soles of the feet or palms of the hands. Inability to give informed consent. Known hypersensitivity to adhesive rings.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allan C Halpern, MD
Organizational Affiliation
Memorial Sloan-Kettering Cancer Center, Manhattan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ashfaq Marghoob, MD
Organizational Affiliation
Memorial Sloan Kettering Cancer Center, Hauppauge
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Abel Torres, MD
Organizational Affiliation
Loma Linda Univeristy Adventist Health Sciences Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lisa Beck, MD
Organizational Affiliation
University of Rochester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Harold S Rabinovitz, MD
Organizational Affiliation
Skin and Cancer Associates, Plantation Fl.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Abel Torres, MD
Organizational Affiliation
VA Loma Linda Health Care System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loma Linda University
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
Facility Name
VA Loma Linda Health Care System
City
Loma Linda
State/Province
California
ZIP/Postal Code
92357
Country
United States
Facility Name
Skin and Cancer Assoicates
City
Plantation
State/Province
Florida
ZIP/Postal Code
33324
Country
United States
Facility Name
Memorial Sloan-Kettering Cancer Center
City
Hauppauge
State/Province
New York
ZIP/Postal Code
11788
Country
United States
Facility Name
Memorial Sloan-Kettering Cancer Center
City
Manhattan
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Facility Name
University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14534
Country
United States

12. IPD Sharing Statement

Learn more about this trial

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

We'll reach out to this number within 24 hrs